Gilead Says Veklury Gets EUA From FDA to Treat Patients With Moderate Covid-19

   By Stephen Nakrosis

Gilead Sciences, Inc. on Friday said the Food and Drug Administration expanded the Emergency Use Authorization for Veklury, permitting use of the investigational antiviral Veklury, or remdesivir, to treat all hospitalized patients with Covid-19.

Previously, the EUA allowed for the use of Veklury to treat patients hospitalized with severe Covid-19, the company said.

Merdad Parsey, the company's chief medical officer, said "As we learn more about Covid-19 and we further establish the efficacy and safety profile of Veklury, we see benefit to making the drug available to patients at earlier stages of the disease. Today's action by the FDA enables physicians to consider a broader range of eligible patients to potentially receive Veklury."

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

August 28, 2020 17:27 ET (21:27 GMT)

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024